JP Morgan Reinstates Neutral on Nektar Therapeutics, Announces $65 Price Target
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.
JP Morgan analyst Jessica Fye reinstates Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and announces $65 price target.